soul trial oral semaglutide cardiovascular outcomes 2024 nejm 2025 Oral Semaglutide Reduces Cardiovascular Events in People with Ongoing #GLP1 -RA Trials on – soul trial semaglutide (NEJM 2025):

ng gi sn phm cn thnCht lng sn phm ok thch Phm Ngc Trm mua ti rocy.vn c xp hng 5 5 sao Ln u mua shop nhng thy kh ng, t cch ng gi n thi t vn u rt tt

To view a copy of this licence, visit About this article Cite this article Vaughan, O.R., Giussani, D.A

Results: Nausea, vomiting, diarrhea, and constipation were the most frequently reported GI adverse events, generally dose-dependent and transient

2024;doi:10.1056/NEJMoa2403347) demonstrated that addition of semaglutide (Ozempic/Wegovy, Novo Nordisk) to an SGLT2 inhibitor showed no renal protective effect (HR = 1.07, 95% CI 0.69-1.67), although the number of subjects receiving an SGLT2 (16%) in this study was relatively small

Most antidepressants and anti-anxiety medications are weight-neutral or tend to cause some weight gain

It has the stronger top-line weight-loss signal